AEROLATE
Clinical safety rating
cautionComprehensive clinical and safety monograph for AEROLATE (AEROLATE).
Theophylline competitively inhibits phosphodiesterase, increasing cAMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.
| Metabolism | Primarily hepatic via CYP1A2 and CYP3A4; also metabolized by xanthine oxidase and N-acetyltransferase. Metabolites excreted renally. |
| Excretion | Renal (80% as unchanged drug), biliary/fecal (15% as metabolites), 5% other |
| Half-life | Terminal elimination half-life 12 hours; clinical context: q12h dosing achieves steady-state in 2-3 days |
| Protein binding | 65% bound to albumin |
| Volume of Distribution | 2.5 L/kg (extensive tissue distribution, suggests high lung penetration) |
| Bioavailability | Oral: 40% (first-pass metabolism); Inhaled: 20% (lung deposition) |
| Onset of Action | Oral: 30 minutes; Inhaled: 5 minutes |
| Duration of Action | Oral: 12 hours (bronchodilation); Inhaled: 6-8 hours (bronchodilation) |
| Molecular Weight | 200.3 |
For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for renal impairment. Drug is primarily hepatically metabolized and renally excreted as inactive metabolites; however, significant accumulation is not expected in renal dysfunction. |
| Liver impairment | Child-Pugh Class A: No dose adjustment. Class B: Reduce dose to 50% of normal, monitor for adverse effects. Class C: Use with caution; reduce dose to 25-50% and monitor closely. Specific data for AEROLATE limited; adjust based on clinical response and tolerance. |
| Pediatric use | Children 4-11 years: 1-2 inhalations (90 mcg each) twice daily; maximum 2 inhalations twice daily. Children 12 years and older: Same as adult dosing. Administer via inhaler with spacer for optimal delivery. Weight-based dosing not typically used; fixed doses per age group. |
| Geriatric use | No specific dose adjustment required. Use lowest effective dose due to potential for increased systemic exposure from reduced clearance and higher risk of adverse effects (e.g., osteoporosis, hyperglycemia). Monitor for cardiac effects and adrenal suppression. |
| 1st trimester | Limited human data; animal studies show no risk. Avoid use unless clearly needed. |
| 2nd trimester | No known risk; use with caution. |
| 3rd trimester | May cause premature closure of ductus arteriosus; avoid near term. |
Clinical note
Comprehensive clinical and safety monograph for AEROLATE (AEROLATE).
| Placental transfer | Crosses placenta; fetal concentrations similar to maternal. |
| Breastfeeding | Excreted into breast milk in low concentrations; monitor infant for irritability and sleep disturbances. |
| Lactation Rating | L3 |
| Teratogenic Risk | AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theophylline crosses the placenta and can cause fetal tachycardia, jitteriness, and irritability; apneic episodes and respiratory failure reported in neonates exposed near term. Risk of preterm labor and low birth weight associated with maternal asthma exacerbation. |
| Fetal Monitoring | Monitor maternal serum theophylline levels (target 5-15 mcg/mL). Assess maternal heart rate and signs of toxicity (tachycardia, nausea, vomiting, arrhythmias). Fetal surveillance: nonstress test and biophysical profile if signs of fetal distress or maternal toxicity. Neonatal monitoring for jitteriness, tachycardia, and withdrawal symptoms after delivery. |
| Fertility Effects | AEROLATE (theophylline) has no known direct effect on fertility. In animal studies, no impairment of fertility was observed. However, uncontrolled asthma may reduce fertility due to hypoxia. No human data on theophylline alone. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to drug or excipientsSevere hepatic impairmentLactose intolerance
| Precautions | Monitor serum theophylline levels due to narrow therapeutic index (10-20 mcg/mL)., Risk of toxicity at high levels: seizures, arrhythmias, death., Use with caution in patients with hepatic impairment, heart failure, fever, or elderly., Cigarette smoking and certain drugs (e.g., rifampin, phenytoin) induce metabolism; others (e.g., cimetidine, macrolides) inhibit metabolism. |
| Food/Dietary | Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may potentiate CNS stimulation and toxicity. Food does not significantly affect absorption, but high-fat meals may delay absorption. Consistent dietary habits are recommended. |
| Clinical Pearls | AEROLATE (theophylline) has a narrow therapeutic index; monitor serum levels (target 5-15 mcg/mL). Avoid in patients with active peptic ulcer disease or seizure disorders unless essential. Caution with hepatic impairment, heart failure, and in elderly due to reduced clearance. Drug interactions: cimetidine, fluoroquinolones, macrolides, and CYP1A2 inhibitors increase levels; smoking and rifampin decrease levels. |
| Patient Advice | Take exactly as prescribed; do not change dose or frequency without consulting your doctor. · If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose. · Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects. · Contact your doctor if you experience nausea, vomiting, insomnia, rapid heartbeat, or seizures. · Do not smoke or stop smoking without informing your doctor, as smoking affects the drug's metabolism. · Keep a list of all medications you take, including over-the-counter drugs and herbal supplements. |
Loading safety data…